ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 147,51
0,89%
Dow Jones
38 884,26
0,08%
DAX
18 530,87
0,50%
Brent Oil
82,205
-0,80%
Bitcoin
62 430,24
0,15%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Chinook Therapeutics Inc (KDNY)

  7. Chinook Therapeutics Inc (KDNY) Actualités

KDNY

Chinook Therapeutics (KDNY)

Chinook Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KDNY
DateHeureSourceTitreSymboleSociété
22/11/202322h15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:KDNYChinook Therapeutics Inc
21/08/202319h21Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:KDNYChinook Therapeutics Inc
17/08/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KDNYChinook Therapeutics Inc
11/08/202323h02Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:KDNYChinook Therapeutics Inc
11/08/202322h39Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:KDNYChinook Therapeutics Inc
11/08/202322h35Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:KDNYChinook Therapeutics Inc
11/08/202322h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KDNYChinook Therapeutics Inc
11/08/202322h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KDNYChinook Therapeutics Inc
07/08/202322h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KDNYChinook Therapeutics Inc
01/08/202313h05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KDNYChinook Therapeutics Inc
28/07/202314h00GlobeNewswire Inc.Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA NephropathyNASDAQ:KDNYChinook Therapeutics Inc
10/07/202322h01Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:KDNYChinook Therapeutics Inc
20/06/202315h06Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:KDNYChinook Therapeutics Inc
20/06/202315h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KDNYChinook Therapeutics Inc
17/06/202313h15GlobeNewswire Inc.Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) CongressNASDAQ:KDNYChinook Therapeutics Inc
12/06/202322h00GlobeNewswire Inc.Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) CongressNASDAQ:KDNYChinook Therapeutics Inc
12/06/202316h40Dow Jones NewsTrending: Novartis Buying Chinook Therapeutics for Up to $3.5 BillionNASDAQ:KDNYChinook Therapeutics Inc
12/06/202315h42Edgar (US Regulatory)Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)NASDAQ:KDNYChinook Therapeutics Inc
12/06/202314h09Dow Jones NewsFlurry of European Companies Engaged in Acquisitions, Asset Sales Monday -- at a GlanceNASDAQ:KDNYChinook Therapeutics Inc
12/06/202307h53Dow Jones NewsNovartis to Acquire Chinook Therapeutics for Up to $3.5 BillionNASDAQ:KDNYChinook Therapeutics Inc
12/06/202307h00GlobeNewswire Inc.Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AGNASDAQ:KDNYChinook Therapeutics Inc
01/06/202301h26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KDNYChinook Therapeutics Inc
16/05/202314h00GlobeNewswire Inc.Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney DiseaseNASDAQ:KDNYChinook Therapeutics Inc
09/05/202322h10Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KDNYChinook Therapeutics Inc
09/05/202322h00GlobeNewswire Inc.Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdatesNASDAQ:KDNYChinook Therapeutics Inc
05/05/202322h05GlobeNewswire Inc.Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KDNYChinook Therapeutics Inc
05/05/202322h00GlobeNewswire Inc.Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) CongressNASDAQ:KDNYChinook Therapeutics Inc
28/04/202323h43Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:KDNYChinook Therapeutics Inc
27/04/202322h00GlobeNewswire Inc.Chinook Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:KDNYChinook Therapeutics Inc
17/04/202322h52Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:KDNYChinook Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KDNY

Dernières Valeurs Consultées

EU
CS
Axa
NASDAQ
NVDA
NVIDIA
FTSE
UKX
FTSE 100
NASDAQ
AAPL
Apple
NASDAQ
MSFT
Microsoft
EU
PX4
SBF 120
EU
RI
Pernod Ricard
EU
BNP
BNP Paribas
NYSE
DIS
Walt Disney
EU
ORA
Orange
NASDAQ
GOOGL
Alphabet
EU
SGO
Cie de SaintGobain
EU
EN
Bouygues
EU
DG
Vinci
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés